Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.25.

Several research firms have recently weighed in on MIST. Zacks Research upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Wells Fargo & Company cut their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Tuesday, July 14th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MIST. Strategic Family Wealth Counselors L.L.C. bought a new stake in Milestone Pharmaceuticals during the 4th quarter valued at $25,000. Eaton Financial Holdings Company LLC bought a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth $26,000. Welch & Forbes LLC bought a new position in shares of Milestone Pharmaceuticals in the first quarter worth $30,000. Bank of America Corp DE boosted its holdings in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the period. Finally, Cetera Investment Advisers purchased a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at $42,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Trading Up 3.4%

Shares of MIST stock opened at $1.22 on Friday. The company has a 50 day moving average of $1.24 and a 200-day moving average of $1.55. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06. The firm has a market cap of $151.89 million, a P/E ratio of -1.79 and a beta of 0.98.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.26). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $30.11 million. Sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.83 earnings per share for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.